Details of the Drug Combinations

General Information of This Drug (ID: DMD9KYF)

Drug Name

LY3023414 DMD9KYF

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
CP-868596 + LY3023414	DC578PJ	CP-868596	Hodgkin lymphoma (Cell Line: L-1236)	[3]
LY3023414 + GDC-0077	DCHHHDH	GDC-0077	DD2 (Cell Line: DD2)	[4]
LY3023414 + Methotrexate	DCVNIFZ	Methotrexate	Hepatoblastoma (Cell Line: HB3)	[3]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT02549989) Study of LY3023414 for the Treatment of Recurrent.
3	Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.